false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Best of IGCS 2022 Annual Global Meeting
How do we define non-eligible for Platinum in Ovar ...
How do we define non-eligible for Platinum in Ovarian Cancer: Impact of prior therapies and novel strategies for treatment - Industry Symposium by Novocure
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video transcript is a symposium on non-eligibility for platinum-based therapy in ovarian cancer. The symposium is sponsored by Novacure and the Ju-Ju Foundation. The panel of speakers includes Dr. David O'Malley, Dr. Bradley Monk, Dr. Kathleen Moore, Dr. Vonda Salutari, Dr. Isabel Rae-Cucard, and Dr. Ahmed Oza. The symposium aims to increase knowledge on defining non-eligibility for platinum-based therapy, impact of prior therapies, PARP resistance, and novel strategies for treatment. <br /><br />Dr. Monk discusses the use of platinum-based therapy, definition of platinum-resistant recurrent ovarian cancer, and the role of bevacizumab in treatment. Dr. Rae-Cucard presents her talk on PARP resistance, discussing mechanisms and potential factors that can predict resistance to PARP inhibitors. The video also mentions ongoing clinical trials exploring combination therapies and various strategies, such as targeting the replication fork and using gemcitabine-induced replication stress.<br /><br />Other strategies discussed include the use of a PA3 kinase inhibitor to induce a BRCA-like phenotype, downregulate proteins involved in DNA damage response, and the potential of novel therapies such as TAS-102 and TTF. The need for further research and biomarker-driven studies is emphasized to better understand and treat platinum-resistant ovarian cancer.<br /><br />In summary, the video explores different avenues of investigation to address the unmet needs in platinum-resistant ovarian cancer, including combination therapies, targeting replication fork, and novel therapies. The importance of further research and biomarker-driven studies is highlighted throughout the symposium.
Keywords
symposium
non-eligibility
platinum-based therapy
ovarian cancer
Novacure
Ju-Ju Foundation
panel of speakers
PARP resistance
combination therapies
replication fork
research
biomarker-driven studies
Contact
education@igcs.org
for assistance.
×